OPTH · Optimi Health Corp.

Optimi Health Corp. operates as a vertically integrated GMP-compliant manufacturer of MDMA and botanical psilocybin, holding rare Health Canada DEL/DL licenses that enable legal production/export of controlled psychedelics. This positions it ahead of most psychedelic peers stuck in clinical phases, with current revenue from Australia's Authorised Prescribers Scheme (PTSD/TRD prescriptions) and Canada SAP/clinical trials. FY2025 revenue reached C$426K (71% drug products), but persistent losses (C$3.7M net loss, C$27M accumulated deficit) underscore high burn amid facility buildout and regulatory investments. The $15M Nasdaq IPO (2.5M shares at $6-8) provides critical capital for production scaling (29%), U.S./Israel expansion (18%), and working capital (53%), funding ~12 months runway while targeting DEA rescheduling/FDA pathways.

Financially, post-1:30 reverse split, 3.2M shares outstanding dilute to 5.7M (18% new money), with insiders retaining ~18% post-offering. No profitability yet, but Australian traction (shipments to Mind Medicine) validates model; U.S. TAM (12M PTSD/9M TRD patients) dwarfs current ops if rescheduling occurs. GMP moat via facilities/labs supports clinical supply (e.g., Israel Phase 2, Canada Phase 2b) and future generics post-exclusivity.

Risks center on regulatory hurdles: U.S. Schedule I blocks sales (needs FDA+DEA action); license loss halts ops; no patents expose to copycats. Foreign private issuer status reduces governance/reporting burdens but limits protections. Management's operational experience (Stevens sourcing, Safariks cannabis ops) aids execution, though insider loans/debt (C$6.4M) signal funding constraints. Offering succeeds only if Nasdaq approves; failure aborts IPO. Overall, high-risk/high-reward bet on psychedelics legalization, with GMP infrastructure as key differentiator.